ADMIT THERAPEUTICS
ADmit Therapeutics is a biotechnology company that specializes in the development of early Alzheimer's disease diagnosis tests. The company's test is based on an epigenetic analysis in blood samples, covering the analysis of a large number of methylcytosines in mtDNA by next-generation sequencing, enabling medical practitioners with an easy way to detect early-stage Alzheimer.
ADMIT THERAPEUTICS
Industry:
Biotechnology Health Care Health Diagnostics Pharmaceutical
Founded:
2017-01-01
Address:
Barcelona, Catalonia, Spain
Country:
Spain
Website Url:
http://www.admit-therapeutics.com
Total Employee:
1+
Status:
Active
Total Funding:
225.05 K USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Google Tag Manager Google Universal Analytics Global Site Tag
Similar Organizations
4D Lifetec
4D Lifetec is a biotechnology company promoting and developing screening and test systems for molecular diagnostics.
Disarm Therapeutics
Disarm Therapeutics is a biotechnology company developing disease-modifying therapeutics for patients with axonal degeneration.
Tiburio Therapeutics
Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.
Current Employees Featured
Founder
Investors List
Ship2B
Ship2B investment in Seed Round - ADmit Therapeutics
GENESIS Ventures
GENESIS Ventures investment in Seed Round - ADmit Therapeutics
Official Site Inspections
http://www.admit-therapeutics.com
- Host name: 185.242.249.42-ip.somvera.cat
- IP address: 185.242.249.42
- Location: Callus Spain
- Latitude: 41.8641
- Longitude: 1.714
- Timezone: Europe/Madrid
- Postal: 08262
More informations about "ADmit Therapeutics"
ADmit THERAPEUTICS - test for an early AD detection.
Admit therapeutics receives accreditation from college of american pathologists Barcelona, Spain โ November 14, 2024. The Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to ADmit โฆSee details»
ADmit Therapeutics - Crunchbase Company Profile & Funding
ADmit Therapeutics may be growing as it has successfully secured 5.4 million euros in a funding round. This capital injection indicates investor confidence and provides the financial resources โฆSee details»
ADmit Therapeutics - The Org
ADmit Therapeutics is a biotechnology company that specializes in the development of early Alzheimer's disease diagnosis tests. The company's test is based on an epigenetic analysis in โฆSee details»
Team - ADmit THERAPEUTICS - test for an early AD detection.
She is a professional with 19 years experience in Intellectual Property, especially in the fields of biotechnology, biomedicine and medtech. She created her own project of patent consultancy โฆSee details»
ADmit Therapeutics S.L. | Alzheimer's Drug Discovery Foundation
Apr 15, 2020 ADmit Therapeutics S.L. Marta Barrachina, PhD, MBA | Catalunya, Spain. Project Overview. Biotechnology/For Profit Organization Type; $497,652 Funding Amount; 4/15/20 โ โฆSee details»
ADmit THERAPEUTICS - test for an early AD detection. Alzheimer's โฆ
ADmit THERAPEUTICS - test for an early AD detection. Alzheimer's disease. Accionistas; en | es; Accionistas. en es . Ferran Prat Marta Barrachina Santiago Lozano Maite Fibla . Tweets by โฆSee details»
ADmit Therapeutics - ASEBIO
ADmit Therapeutics, S.L. is a company spin-off from Bellvitge Biomedical Research Institute (IDIBELL), created in December 2017, and focused on the development and โฆSee details»
ADmit Therapeutics - Crunchbase Company Profile & Funding
ADmit Therapeutics is a biotechnology company intended to develop a test for early diagnosis of Alzheimer. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. โฆSee details»
ADmit Therapeutics - Funding, Financials, Valuation & Investors
Seed Round - ADmit Therapeutics . 1: obfuscated. obfuscated โ Investors. Edit Investors Section. Number of Lead Investors 3. Number of Investors 7. ADmit Therapeutics is funded by โฆSee details»
The IDIBELLโs spin-off ADmit therapeutics closes a โฌ5.4 โฆ
Oct 6, 2023 ADmit Therapeutics is a biotechnology company founded at the end of 2017 as a spin-off from the Bellvitge Biomedical Research Institute (IDIBELL). The company is focused on the development and commercialization of a new โฆSee details»
ADmit - ADmit THERAPEUTICS - test for an early AD detection.
ADmit Therapeuticsโ vocation consists in building a strong portfolio of projects. The first one will be based in the prognosis of AD dementia at Mild Cognitive Impairment stage. But ADmit โฆSee details»
ADmit Therapeutics S.L. | Alzheimer's Drug Discovery Foundation
Feb 18, 2023 ADmit Therapeutics S.L. Marta Barrachina, PhD, MBA | Catalunya, Spain. MAP-AD, a revolutionary Methylation Profiling approach for early diagnosis of Alzheimerโs Disease. โฆSee details»
ADmit Therapeutics Company Information - Funding, Investors
ADmit Therapeutics, based in Barcelona, is a promising company in the Alzheimer's disease space, focusing on early detection technology. Unlike traditional methods that rely on later โฆSee details»
ADmit Therapeutics Company Profile - Office Locations ... - Craft
ADmit Therapeutics Summary. Company Summary. Overview. ADmit Therapeutics is a company engaged in the development of an early Alzheimer's disease diagnosis test. It is based on an โฆSee details»
ADmit Therapeutics - PitchBook
ADmit Therapeutics General Information Description. Developer of a medical diagnostic test intended to come up with early detection for Alzheimer's disease. The company's diagnostic โฆSee details»
A Methylation Profiling Diagnostic for Early Diagnosis of ... - CORDIS
Oct 16, 2024 To meet this market need, ADmit Therapeutics, an innovative diagnostics SME, aims to deliver MAP-AD: an automated epigenetic analysis platform for accurate prediction of โฆSee details»
News - ADmit THERAPEUTICS - test for an early AD detection.
About ADmit Therapeutics. ADmit Therapeutics is a medtech company leading the development of novel blood-based mitochondrial biomarkers to revolutionize the early detection of โฆSee details»
Contact - ADmit THERAPEUTICS - test for an early AD detection ...
ADmit; Technology; Team; Partners; News; Contact; test for an early AD detection Alzheimer's disease . Contact For more information. Carrer Joan XXIII, 10 08950 Esplugues de Llobregat โฆSee details»
admit-therapeutics.com Reviews: Is this site a scam or legit?
After you read why we gave admit-therapeutics.com such a low score, please tell us if you've had a bad experience with this website in the comments below.. Scam Detectors Most Trusted โฆSee details»
Technology - ADmit THERAPEUTICS - test for an early AD โฆ
PROGNOSIS. Our IVDR represents the determination of biomarkers non-related with ฮฒ-amyloid nor tau. Therefore, our unique value proposition is that our technology is based on an โฆSee details»